NCT06067568

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of Two Lutikizumab Formulations and to Evaluate Lutikizumab Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Lutikizumab Dose A	Injection; subcutaneous (SC)
DRUG	Lutikizumab Dose B	Injection; subcutaneous (SC)

Timeline

• Start date: 2023-09-28
• Primary completion: 2024-02-26
• Completion: 2024-02-26
• First posted: 2023-10-05
• Last updated: 2024-03-15

Locations

3 sites across 1 country: United States